Akero Therapeutics, Inc. (AKRO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 20.51 |
| Open | 20.44 |
| Bid | 20.67 x 500 |
| Ask | 20.80 x 200 |
| Day's range | 20.42 - 21.04 |
| 52-week range | 11.25 - 58.38 |
| Volume | |
| Avg. volume | 1,382,112 |
| Market cap | 1.431B |
| Beta (5Y monthly) | -0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.89 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.00 |
Insider MonkeyBillionaire Steve Cohen and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at the Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Steve Cohen and Insiders Are Buying These 5 Stocks. Investors are holding their breath ahead of the key Fed decision about interest rates. While analysts expect the […]
ZacksMadrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
ZacksIonis (IONS) Drug Meets Mid-Stage MASH Study Goals
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
© 2024 Yahoo. All rights reserved.